All In Biotech

Drug Trial Radar · NCT06834282

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Apr 7, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

Conditions

  • AML
  • Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia

Interventions

  • CER-1236Drug

    an autologous chimeric engulfment receptor T-cell

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy

  • FludarabineDrug

    Lymphodepleting chemotherapy

  • MesnaDrug

    Chemoprotectant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Part 1)Time frame: 2 year
  2. Incidence of dose-limiting toxicities (DLTs) of CER-1236 Monotherapy - (Part 1)Time frame: 28 days
  3. Estimation of the objective response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD) negativity rates - (Part 2)Time frame: 2 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Sarah Cannon Research Insitute

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.